Sonoma Pharmaceuticals, Inc., based in Boulder, Colorado, specializes in producing hypochlorous acid products for various health care uses, including wound and animal care, and has 8 full-time employees. Its key products include Regenacyn Advanced Scar Gel, MicrocynAH for animal wounds, and several other care gels and cleansers launched after its 2007 IPO.
Sonoma Pharmaceuticals (SNOA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Sonoma Pharmaceuticals's actual EPS was -$1.40, missing the estimate of -$1.22 per share, resulting in a -14.38% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
